![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
|
Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Caption: Wolfram Goessling, M.D., Ph.D., and colleagues demonstrated that an innovative experimental treatment for boosting the effectiveness of stem-cell transplants with umbilical cord blood has a favorable safety profile in long-term animal studies.
Credit: Sam Ogden
Usage Restrictions: None
Related news release: Enhanced cord blood stem cell transplants safe in long-term studies
|